Introduction
The promyelocytic leukaemia zinc finger (PLZF) gene was identified through the characterization of a rare case of acute promyelocytic leukaemia (APL) with a variant chromosomal translocation t(11;17)(q23;q21) and resistance to therapy with all-trans-retinoic acid (ATRA) (Chen et al., 1993a, b; Licht et al., 1995) . Leukaemic cells harbouring the above reciprocal chromosomal translocation, which fuses the PLZF and the retinoic acid receptor-a (RARa) genes, express PLZF-RARa and RARa-PLZF fusion proteins. The wild-type PLZF protein is a sequence-specific transcription factor that is characterized by nine Kru¨ppel-like C 2 -H 2 zinc fingers and an N-terminal POZ domain (Li et al., 1997; Guidez et al., 1998) . POZ is a conserved structural motif found in a number of pox and zinc-finger proteins, which has been shown to mediate homo/heterodimerization as well as nuclear localization (Bardwell and Treisman, 1994; Dong et al., 1996; Ahmad et al., 1998; Guidez et al., 1998) . The POZ domain appears to be critical for the function of the PLZF protein as a transcriptional repressor . Studies from our laboratories and others have shown that PLZF can repress transcription through recruitment of nuclear receptor corepressors (N-CoR or SMRT)/histone deacetylase (HDAC) complexes via its POZ domain (Hong et al., 1997; David et al., 1998; Grignani et al., 1998; Guidez et al., 1998; Lin et al., 1998; Wong and Privalsky, 1998 ). An additional transcriptional repression domain, which binds the ETO protein and lies between the POZ domain and the zinc finger region, has also been identified (Melnick et al., 2000b) . PLZF also possesses an acidic region, which when fused to a GAL4 DNA binding domain (DBD) functions as a transcriptional activation domain (Li et al., 1997) . However, whether PLZF itself functions to activate transcription under physiological conditions is not known.
The inability of t(11;17)(q23;q21) APL patients to respond to therapy appears to correlate with the ATRAinsensitive interaction of PLZF-RARa with the corepressor/histone deacetylase complex, mediated through the fused N-terminal PLZF domains (Hong et al., 1997; David et al., 1998; Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al., 1998; Wong and Privalsky, 1998) . However, the ability of PLZF-RARa transgenic mice to respond to supraphysiological con-centrations of ATRA (He et al., 1998) further suggests that expression of the reciprocal fusion protein, RARa--PLZF, may be required for a complete differentiation arrest. Consistent with this hypothesis, recent work has shown that in transgenic animals RARa-PLZF cooperates with PLZF-RARa in the establishment of RAresistant APL, presumably by providing an additional hit in leukaemogenesis (He et al., 2000) . This may involve de-regulation of PLZF target genes by RARa-PLZF.
Studies addressing the expression patterns of PLZF in haematopoietic progenitor cells and the developing embryo suggest that it may play a role in regulating cellular growth and/or differentiation Reid et al., 1995) . Overexpression of PLZF in the myeloid progenitor cell line 32Dcl13 results in growth suppression and inhibition of differentiation (Shaknovich et al., 1998) . Consistent with these findings, cyclin A2 has been identified as a potential PLZF target gene (Yeyati et al., 1999) . Furthermore, the dynamic and rhombomere-specific pattern of PLZF expression in the developing murine and chick hindbrain (Wilkinson, 1993; Cook et al., 1995) overlaps with that of a number of other factors (Sek1, Krox-20 and Hoxb2), suggesting that PLZF may be involved in regulating segmentation/ differentiation during central nervous system (CNS) development. Here we demonstrate that PLZF can bind to a sequence in the enhancer that controls upregulation of the Hoxb2 gene in rhombomeres 3 and 5. These results suggest that Hoxb2 may be a direct target for regulation by PLZF in the developing hindbrain. As Hox genes are known to control proliferation and differentiation in the haematopoietic system as well as during development (Magli et al., 1997) , disruption of PLZF by the t(11;17)(q23:q21) translocation in APL may contribute to leukaemogenesis by causing deregulated Hox gene expression.
Results
PLZF and RARa-PLZF bind to a site derived from the Hoxb2 r3/r5 enhancer During mouse embryogenesis PLZF is expressed in a segmental pattern in the hindbrain . The specific temporal pattern of PLZF expression observed between 8.5 and 9.5 dpc in CNS, particularly in r3 and r5, coincides and overlaps with changing levels of the Hoxb2 expression, suggesting that in coordination with other factors PLZF may play a role in regulating Hoxb2 expression. Rhombomere-specific expression of Hoxb2 is mediated by a 693 bp r3/r5 enhancer, which contains a number of cis-regulatory elements including multiple binding sites for another Kru¨ppel-like zincfinger transcription factor Krox20 (Sham et al., 1993; Vesque et al., 1996) . To investigate the possibility that PLZF may also regulate Hoxb2 expression, we first examined the r3/r5 enhancer sequence for the presence of potential PLZF binding sites. This approach revealed the presence of a single 8 bp motif completely distinct from the Krox20 binding sites (see Figure 1a) , with homology to the previously identified LexA operator (LexAop)-derived PLZF binding site (Sitterlin et al., 1997; Guidez et al., 1998) . A 32 P-end-labelled oligonucleotide (PLZF RE ) encompassing this potential PLZF binding site plus an additional r3/r5 flanking sequence was used as a probe in electrophoretic mobility shift assays (EMSAs) to test for binding by the PLZF protein in vitro. Using nuclear extracts from KG1 cells, which endogenously express low levels of PLZF, the PLZF RE probe generated a high molecular weight complex that could be supershifted by anti-PLZF monoclonal antibodies (Figure 1b, lanes 1 and 4) . Furthermore, the slower migrating complexes were effectively competed by excess unlabelled probes containing PLZF binding sites (LexAop or PLZF RE oligonucleotides, Figure 1b , lanes 2 and 3), but not by nonspecific competitor oligonucleotides (not shown). Additionally, nuclear extracts from 293T cells transiently transfected with a FLAG-tagged PLZF expression vector generated protein-DNA complexes, which comigrated with those seen using nuclear extracts from KG1 cells (293T/ In order to define the minimal PLZF response element (PLZF-RE), point mutation analysis was carried out on the 24 bp Hoxb2 r3/r5 sequence, which contains the potential PLZF binding site. A series of competitor oligonucleotides (mut 7-21 and data not shown) was used to test the effect on PLZF binding of sequential point mutations across the entire PLZF RE probe. Binding data for mut 7-21 are summarized in Table 1 . Substitution (base transversion) of any of the nucleotides within the TACTGTA motif resulted in the loss of ability to compete with the wild-type 32 P-labelled PLZF RE probe for binding of PLZF ( Figure 2a , lanes 5-11). Mutation of any of the nucleotides flanking the above motif, on the other hand, had no effect (lanes 3, 4, 12-15, and data not shown). It is worth noting that the TACTGTA element defined by the above analysis appears to be an inverted repeat separated by a single nucleotide. Increasing the spacing between its two half sites (mut 29) resulted in a loss of the ability to compete for PLZF binding (Table 1 and data not shown). Substitution of A for the central T nucleotide was permissive for binding of PLZF (mut 30, Table 1 and data not shown).
To test whether the TACTGTA motif would be sufficient to confer PLZF binding, competition EMSAs were carried out to test the binding of PLZF to a single core TACTGTA element in a heterologous background (mut 31, see Table 1 ). Mut 31 competed only weakly for binding of PLZF to the wild-type PLZF RE probe (Figure 2b , see lanes 5-7), suggesting that residues lying outside of the core binding motif defined by point mutation analysis may also be required for efficient binding. Consistent with this possibility, adding back the wild-type C nucleotide immediately downstream of the TACTGTA motif dramatically increased the ability of the resulting oligonucleotide (mut 34, see Table 1 ) to compete for PLZF binding (Figure 2b, lanes 11-13) . In contrast, the addition of GC upstream of the core motif (mut 33, see Table 1 ) had no effect (Figure 2b , lanes 8-10). Thus, although point mutation of the downstream C residue in the context of the wild-type PLZF RE oligonucleotide was found to have no effect on its ability to compete for PLZF binding (mut 16, see Table 1 and Figure 2a , lane 12), it nevertheless made an important contribution in the absence of other wild-type flanking sequences. In the light of these results, we define the minimal PLZF DNA binding sequence as 5
0 . It is worth pointing out that in contrast to results obtained for other POZ domain proteins (Bardwell and Treisman, 1994; Deweindt et al., 1995; Seyfert et al., 1996) , the PLZF POZ domain did not impede binding of PLZF to DNA (Figure 2c (Sham et al., 1993) . The region of homology with the LexAop-derived PLZF binding site (Sitterlin et al., 1997 Although the binding of PLZF to the TACTGTA element alone (mut 31) was relatively weak (Figure 2c , lanes 5 and 6), PLZF bound with considerably higher affinity to a probe containing a second copy of the TACTGTA motif 10 nucleotides downstream of the first site (mut 32, Figure 2c , lanes 9 and 10). In fact, PLZF appeared to bind this probe more strongly than the wildtype PLZF RE probe (compare lanes 9 and 10 with 1 and 2). Changing the nucleotide spacing in between the two copies of the core-binding element did not affect the enhanced binding of PLZF (data not shown). Furthermore, the POZ domain appeared to be required for this effect, as the binding of PLZFDPOZ was only slightly enhanced by the presence of a second TACTGTA sequence ( Figure 2c, GCCTTcCTGTACAGGACTCCCTTC
Point mutations are shown in lowercase letters and in bold. The ability of a given oligonucleotide to bind PLZF is indicated by+and À signs (++++ indicates strong binding and À indicates no ability to bind PLZF) Figure 2 Point mutation analysis defines a minimal PLZF binding site. (a) Mutations within the motif 5 0 -TACTGTA-3 0 disrupt binding of PLZF to the PLZF RE oligonucleotide probe. EMSA shows binding of PLZF (KG1 nuclear extracts) to 32 P-end-labelled double-stranded PLZF RE oligonucleotide probe; in lanes 2-15, a 500-fold molar excess of unlabelled mutant oligonucleotides mut 7-mut 19 (see Table 1 ) was included in the binding reactions, as indicated. The arrowhead indicates the PLZF/DNA complex. (b) PLZF binds more strongly to the element 5 0 -TACTGTAC-3 0 than to 5 0 -TACTGTA-5 0 . Competition EMSA was carried out as in (a), but with unlabelled PLZF RE (lanes 2-4), mut 31 (5-7), mut 33 (lanes 8-10) and mut 34 (lanes 11-13) oligonucleotides as competitors (see Table 1 ). (c) Binding of PLZF is enhanced in the presence of two copies of the minimal site. Lanes 1-4 show binding of PLZF (present in nuclear extracts from KG1 cells or transiently transfected 293T cells), PLZFDPOZ and RARa1-PLZF proteins (expressed transiently in 293T cells) to PLZF RE 32 P-endlabelled double-stranded oligonucleotides. Lanes 5-12 show binding of the same proteins to mutant oligonucleotides mut 31 and mut 32, which contain one and two 5 0 -TACTGTA-3 0 elements respectively (see Table 1 PLZF binds cooperatively to a probe containing multiple binding sites
The observation that the full-length PLZF protein but not PLZFDPOZ bound with higher affinity to a probe (mut 32) containing two TACTGTA motifs as compared with a single copy of this element suggested two possibilities. PLZF may bind cooperatively to DNA containing multiple copies of its minimal binding site, and the POZ domain may confer this cooperativity. This was further examined using a probe containing three copies of the TACTGTAC sequence separated by 10 nucleotides, PLZF-RE(3). A range of concentrations of PLZF-or PLZFDPOZ-containing nuclear extracts were tested by EMSA for binding to the 32 P-end-labelled PLZF-RE(3) oligonucleotide probe. As expected from the above results, PLZFDPOZ protein generated several complexes, which gradually increased in intensity with increasing concentration of expressed protein (Figure 3 , lanes 1-6). On the other hand, full-length PLZF bound strongly to this probe even at lower protein concentrations (lanes 8-13). When the 293T/PLZF nuclear extract was diluted (1 in 15), and tested for binding activity towards the PLZF-RE(3) probe (lanes 14-19), the transition from 0.8 to 1.6 ml extract was found to mark a sharp increase in the level of protein/DNA complexes (compare lanes 17 and 18). This occurred at a much lower protein concentration than would be required to obtain an equivalent result using a probe containing a single PLZF binding site. Furthermore, only one complex was generated, indicating that all binding sites become occupied at once. The DNA-binding specificities of retarded complexes are reflected by competition with unlabelled probe (lanes 7 and 20). These results confirm that PLZF can bind cooperatively to DNA containing multiple copies of its binding site and that the POZ domain is required for cooperative binding.
PLZF represses the activity of a Hoxb2 r3/r5 reporter Having shown that PLZF was able to bind to a sequence present in the Hoxb2 r3/r5 enhancer, we tested its ability to regulate promoter activity when bound to this site in vivo. Transient cotransfection of PLZF with a reporter plasmid (r3/r5-TKluc) containing the entire Hoxb2 r3/r5 enhancer (inserted upstream of luciferase driven by the minimal HSV TK promoter) resulted in a dosedependent repression of the reporter activity in 3T3 cells (Figure 4 ). In contrast, despite its ability to bind to the PLZF-RE, RARa1-PLZF was unable to repress the activity of the above reporter (data not shown). To test whether repression of r3/r5-TKluc by PLZF was dependent on the presence of an intact binding site, point mutations that abrogate binding of PLZF in vitro were introduced into the TACTGTAC motif within the r3/r5 enhancer. In agreement with the in vitro results, PLZF was unable to repress the activity of the resulting mutant reporter, r3/r5mut-TKluc (Figure 4) . Therefore, P-end-labelled double-stranded PLZF-RE(3) probe (see Materials and methods for probe sequence). 0.1, 0.2, 0.4, 0.8, 1.6 and 3.2 ml 293T/PLZF (lanes 1-6) or 293T/PLZFDPOZ (lanes 7-12) nuclear extracts (at 1 mg/ml) were incubated with PLZF-RE(3) probe. Lanes 13-18: 293T/PLZF nuclear extracts were diluted 1/15 using extract from untransfected cells. Filled and open arrowheads indicate the single and multiple protein/DNA complexes generated by PLZF and PLZFDPOZ proteins, respectively. Lanes 7 and 20 indicate competition (c) of protein binding at highest concentration (as in lanes 6 and 19) with excess unlabelled probe PLZF regulates Hoxb2 r3/r5 enhancer S Ivins et al loss of an intact PLZF binding site in the r3/r5 enhancer correlated with the loss of repression by PLZF. In addition, the ability of PLZF to repress transcription was found to be dependent on both intact POZ and DNA-binding domain, as deletion mutants lacking either the POZ domain or the entire zinc-finger region were unable to downregulate r3/r5-TKluc activity (data not shown).
An A/T-rich sequence is required for optimal repression of the Hoxb2 r3/r5 enhancer by PLZF PLZF-mediated repression of reporter genes with either multiple PLZF-REs or the full r3/r5 enhancer was stronger than repression of a reporter containing a single PLZF-RE (data not shown), suggesting that PLZF may cooperate with other sequences within the r3/r5 enhancer. The regulatory sequences governing the upregulation of Hoxb2 in r3 and r5 have been well characterized and include three Krox20 sites (Sham et al., 1993) , as well as a binding site (Box1) for an as yet unknown factor (see Figure 5a ), which cooperates with Krox20 (Vesque et al., 1996) . In order to examine whether PLZF could cooperate with Krox-20 binding sites and/or Box1 sequences, mutant r3/r5 reporters were constructed in which either all three Krox20 binding sites (r3/r5-Kroxmut-tKluc) or the Box1 site (r3/r5-Boxmut-TKluc) were disrupted. Such mutations in the Krox20 binding sites or the Box1 sequence were previously shown to abolish r3/r5 enhancer activity in vivo (Sham et al., 1993; Vesque et al., 1996) . The activity of the r3/r5-Kroxmut-TKluc reporter was not significantly changed relative to its wild-type counterpart (data not shown); furthermore, the ability of PLZF to repress r3/r5 enhancer activity was unaffected by mutations in the Krox20 sites (Figure 5c ). In contrast, mutation of the Box1 site resulted in a loss of repression by PLZF (Figure 5c ) and in a 2-5-fold increase in reporter activity (data not shown). In 3T3 cells, PLZF repressed r3/r5-Boxmut-TKluc activity by only 30%, that is, half the level of repression seen with the wildtype reporter. These results suggest that PLZF may cooperate with an as yet unknown factor (or factors) that binds to the Box1 site. Hence, the Box1 motif appears to bind factors that cooperate with Krox20 or PLZF and enhance or repress transcription from the Hoxb2 enhancer.
As transcriptional repression by PLZF has been shown to be sensitive to histone deacetylase inhibitors (David et al., 1998; Guidez et al., 1998) , we examined, using the chromatin immunoprecipitation (ChIP) assays, whether the effect of PLZF on the r3/r5 enhancer correlated with local changes in histone acetylation. Reporter genes containing the r3/r5 enhancer were coimmunoprecipitated from transfected cells using antibodies to acetylated histone H4. The coimmunopre- cipitated r3/r5 enhancer DNA was then amplified in a semiquantitative fashion using primers spanning the region containing the PLZF binding site. The level of histone H4 acetylation was reflected by the intensity of the amplified DNA fragment. Cotransfection of PLZF expression vector with r3/r5-Tkluc reporter resulted in a lower level of the 359 bp PCR product (relative to the level seen when empty vector was cotransfected), indicating a reduced level of histone acetylation at the r3/r5 enhancer (Figure 5b ). However, in the case of the Box1-mutated reporter, the level of histone acetylation was unchanged in the presence or absence of PLZF. Amplification of input DNA for each sample showed that there was no difference in the amount of DNA present in each cell extract prior to IP (see input DNA lanes). PLZF protein was expressed to a similar level in all samples (data not shown). Taken together, the above results show directly that repression by PLZF involves deacetylation of the histones associated with the promoter region surrounding its binding site, and that mutation of Box1 reduced the ability of PLZF to mediate histone deacetylation at the r3/r5 enhancer in vivo.
PLZF regulates
In order to examine whether the above effects of Box1 mutation were because of reduced binding of PLZF, protein extracts derived from transfected cells were used in EMSAs. As expected, PLZF bound stronger to an oligonucleotide probe containing Box1 and PLZF-RE (PLZF+Box1) than to a probe with a single PLZF-RE (data not shown), or a probe containing a mutant Box1 adjacent to the PLZF-RE (PLZF+mut-Box1) (Figure 5d , compare lanes 1-3 with 4-6). The above results suggest that the nuclear extracts may contain a factor, which on binding to Box1 cooperatively enhances the binding of PLZF to its response element. Furthermore, cooperation with PLZF is required for binding of the unknown factor to Box1, as no specific retarded bands were observed when the PLZF site was mutated (probe mut-PLZF+Box1, lanes 7-9). The results of ChIP experiments also indicated reduced binding of PLZF to DNA sequence containing PLZF-RE and mutated Box1 sequence (Figure 5b ) and corroborate the in vitro binding data. In contrast to an isolated PLZF-RE, in vivo (Figure 5b ) and in vitro (not shown) binding of PLZFDPOZ to DNA containing both PLZF-RE and and Box1 sequences was lower than that of the wild-type PLZF. However, the binding of PLZFDPOZ was independent of the Box1 site (Figure 5b and data not shown), indicating that by analogy to cooperative binding of PLZF to multimerized PLZF-RE the POZ domain is also required for cooperation between PLZF and the unknown factor that binds to the Box1 site.
In vivo cooperation between PLZF and Box1 sites in the developing hindbrain
To examine the functional activity of the PLZF binding site in relation to the Box1 motif in vivo, we used a transgenic expression assay. We previously showed that multiple copies of a double-stranded oligonucleotide containing both the Krox20 and Box1 sites from the mouse Hoxb2 segmental control region would function as a synthetic enhancer capable of mediating reporter expression in r3 and r5 in the developing hindbrain (Vesque et al., 1996) . However, versions that contained either site alone (Krox20 or Box1) had no activity (Vesque et al., 1996) . We therefore generated a similar synthetic control element using the PLZF site and the Box1 motif linked to a lacZ reporter gene and tested its regulatory potential by electroporating it into the developing chick hindbrain (Figure 6 ). This construct, containing the wild-type sequences for these sites (PLZF-Box1; Figure 6e ), functions as an enhancer and directs reporter staining from r6 in the hindbrain anteriorally through to the mid-brain region of the neural tube on the electroporated side (left), but not on the internal control side (Figure 6a ). This activity is dependent upon both the PLZF and Box1 motifs, as multimers containing mutations in either the PLZF site or the Box1 site completely abolish reporter staining in the hindbrain (Figure 6b ,c). This shows that endogenous factors acting through both of these sites are essential for enhancer activity. Furthermore, the patterns of expression directed by the combination of PLZF and Box1 are very different from those seen when Krox20 and Box1 sites are used, suggesting that it is the zinc finger containing proteins that bind to these sites that direct the spatially restricted character of the enhancers.
Interestingly, addition of the Krox20 motif to the wild-type PLZF-Box1 synthetic enhancer changed the patterns of expression. The reporter gene was expressed specifically in r3 and r5 (Figure 6d ), consistent with our previous results demonstrating that the Box1 and Krox20 sites can regulate segmental expression in these domains (Vesque et al., 1996) . However, expression from r6 to the mid-brain generated by the combination of the PLZF and Box1 motifs was absent. Therefore, the presence of all three sites together did not result in additive activities and the Krox20 site appears to have overridden the influence of the PLZF motif.
Discussion
Based on correlations in our previously published expression studies Reid et al., 1995) , we have now identified a PLZF binding site in the regulatory region of the Hoxb2 locus (r3/r5 enhancer), which controls the rhombomere-specific expression pattern of Hoxb2 during hindbrain development (Sham et al., 1993) . We demonstrated the ability of PLZF to bind cooperatively in the presence of multiple copies of this element, and show that it cooperates with another r3/r5 cis-regulatory factor for both DNA binding and transcriptional regulatory activities. Our results suggest that PLZF may form part of a network of transcription factors controlling the spatially and temporally regulated pattern of expression of Hoxb2 in vivo. This raises a number of interesting issues with respect to PLZF, Hox genes and leukaemia.
Properties of PLZF and DNA binding
A series of in vitro binding experiments defined an 8 bp sequence motif (TAC T / A GTAC) capable of efficiently binding the PLZF protein. In analogy with the Drosophila GAGA factor (Espinas et al., 1999; Katsani et al., 1999) , PLZF is able to bind cooperatively in a POZ domain-dependent manner to multiple copies of its binding site. Structural analysis of the PLZF POZ domain has shown that it forms a tight, highly intertwined dimer (Ahmad et al., 1998; Melnick et al., 2000a) , which has the potential to form multimeric structures. Thus, it is possible that the structure of the PLZF POZ domain favours binding to multiple sites. However, in contrast to GAGA, the PLZF POZ domain does not inhibit the binding of PLZF to a single site. Interestingly, even in the case of PLZFDPOZ, it is notable that the binding of more than one molecule of protein seemed to be favoured over binding of a single molecule. This is supported by the more slowly migrating complexes being more intense and appearing at a lower concentration of protein than the more rapidly migrating smaller protein/DNA complexes. Therefore, the zinc-finger region may also mediate a lower level of cooperativity. Our observations that cooperative binding can facilitate the interaction of PLZF with a suboptimal binding site suggest that in the presence of multiple sites a greater degree of degeneracy in the core element may be permissible. However, to date, it is not known whether PLZF binding sites exist in multiple copies in target promoters. Indeed, it is possible that in the context of a promoter containing a number of weak PLZF binding sites, the cooperative binding function of PLZF may facilitate a strong interaction with the promoter, leading to a stronger effect on transcription than that exerted by a single PLZF binding site.
Cooperation of PLZF with A/T-rich motifs
Effective repression of the r3/r5 enhancer reporter by PLZF required both the PLZF-RE motif and Box1. Box1 is an A/T-rich binding site for an as yet unidentified cis-acting factor, which also cooperates with Krox20 to mediate rhombomere-specific expression of Hoxb2 during development (Vesque et al., 1996) . PLZF and the Box1-binding factor may therefore cooperate in vivo to regulate r3/r5 enhancer activity. As the PLZF binding site and Box1 lie almost 300 bp apart within the r3/r5 enhancer, looping out of the intervening sequence may be required for the interaction of PLZF with the Box1-binding factor in vivo. Protein/ protein interactions leading to DNA looping have been demonstrated for Sp1 protein (Mastrangelo et al., 1991; Su et al., 1991) , and have been suggested to account for the synergistic interactions of GATA-1 with Sp1 and EKLF (Merika and Orkin, 1995). The formation of looped domains of active chromatin may facilitate communications between distant regulatory elements. In the case of PLZF and the Box1 factor, the looped-out r3/r5 DNA may be refractory to activation by Krox20 and/or other factors binding to the intervening sequence, leading to the repression seen in the transfection experiments. Alternatively, the interaction may be required to mediate efficient binding of PLZF to the r3/r5 enhancer in vivo, thus facilitating the recruitment of a corepressor/histone deacetylase complex to the enhancer. Supporting this notion, the ChIP assay showed that mutation of Box1 impaired the ability of PLZF to bind to its response element in vivo and to mediate histone deacetylation at the r3/r5 enhancer.
The possibility of cooperation between PLZF and the Box1-binding factor was corroborated by the transgenic reporter assays carried out in chick embryos, in which both PLZF and Box1 sites were essential for lacZ reporter expression in the chick neural tube. Reporter expression closely reflected endogenous PLZF expression in the neural tube. Interestingly, addition of the Krox20 motif resulted in an r3-and r5-specific pattern of expression similar to that obtained using a reporter driven by Box1 and Krox20 sites alone (Vesque et al., 1996) , suggesting that the Krox20 site can override the influence of the PLZF motif. It is not immediately apparent why cooperation between PLZF and Box1 sites results in repression of the r3/r5 reporter in transfected cells, whereas in the transgenic assays these sites activate reporter expression. However, the regulatory effects of PLZF may be promoter and/or cellular context specific. A number of proteins have been shown to both repress and activate transcription; for example, depending on context YY1 can represses or activate transcription of specific genes (Natesan and Gilman, 1993; Shrivastava et al., 1993) . In the case of PLZF, the r3/r5 sequence used in the reporter constructs for the cell transfection studies was larger than that used in the transgenic reporter and this may determine whether PLZF/Box1 cooperativity results in activation or repression. The regulatory activity of PLZF may also be influenced by other cell-specific transcription factors. Taking the above into consideration, it is possible that PLZF has multiple roles in regulating Hoxb2 expression in vivo. For example, in early development, expression of PLZF and Box1 factor throughout the neural tube may be required to establish a baseline of Hoxb2 expression through recruitment of histone deacetylases. The decline of PLZF expression in r3 and r5 is concomitant with the initiation of Krox20 expression. This could lead to the Box1-dependent superactivation of Hoxb2 expression in these rhombomeres. In this model, while the zinc finger proteins PLZF and Krox20 ultimately determine spatial and temporal aspects of Hoxb2 expression, both depend on interactions with the as yet unidentified Box1 factor to exert their transcriptional effects.
PLZF and Hoxb2 as a target gene in haematopoiesis Several Hox genes, including Hoxb2, are expressed in the haematopoietic system and appear to be involved in the regulation of growth and differentiation pathways. Hoxb2 is expressed in a variety of cell types including multipotent CD34
+ bone marrow cells and myeloid/ erythroid progenitors cell (Mathews et al., 1991; VieilleGrosjean et al., 1992; Care et al., 1994; Sauvageau, 1994; Quaranta et al., 1996 ) . A number of lines of evidence have suggested that the induction of Hoxb cluster genes, including Hoxb2, is associated with the simultaneous activation of proliferation and differentiation programmes (Simeone et al., 1990; Care et al., 1994; Giampaolo et al., 1994; Quaranta et al., 1996) . Furthermore, translocations of Hox genes themselves (Borrow et al., 1996; Nakamura et al., 1996) or regulators of Hox gene function or expression such as MLL and PBX1 (Kamps et al., 1990; Nourse et al., 1990; Yu et al., 1995) are implicated in some cases of leukaemia. Thus, in APL it is possible that the fusion proteins RARa-PLZF and PLZF-RARa could disrupt the ability of wild-type PLZF to regulate target genes such as Hoxb2, resulting in the misexpression of such genes and consequent perturbation of cellular growth and differentiation. It is worth noting that evolutionarily conserved PLZF binding sites exist in other Hox genes such as HOXA9 for example (our unpublished results), which itself is involved in an AML-associated translocation (Borrow et al., 1996; Nakamura et al., 1996) , its overexpression is highly correlated with poor prognosis in AML (Golub et al., 1999) and whose overexpression in murine bone marrow cells leads to development of transformed phenotype in vitro and leukaemia in vivo (Kroon et al., 1998) . Significantly, expression of RARa-PLZF alone in transgenic mice has been found to cause myeloid hyperplasia, while expression of RARa-PLZF in addition to PLZF-RARa is required to recapitulate the classical features of APL including resistance to differentiation by ATRA in transgenice mice (He et al., 2000) . The latter results underline the potential role of RARa-PLZF in leukaemogenesis, while our results suggest that the observed effects of RARa1-PLZF in vivo may arise from its ability to bind strongly to the PLZF-RE, thus potentially competing with wild-type PLZF and interfering with transcriptional regulation of PLZF target genes. In support of this, we have observed in transfection experiments that RARa1-PLZF can inhibit repression by PLZF (Figure 7) .
Hoxb2 has been identified as a PLZF target gene with a possible relevance in a number of developmental systems including CNS and haematopoiesis. It is an attractive hypothesis to consider that PLZF may regulate a similar set of target genes in both processes. Although PLZF null mice do not exhibit an obvious haematopoietic phenotype, one cannot rule out a role for PLZF in haematopoiesis. FAZF/ROG, a gene that encodes a protein with DNA binding specificity and expression patterns that are highly similar to those of PLZF (unpublished results), might partially compensate for the lack of PLZF during development (Hoatlin et al., 1999; Miaw et al., 2000) . Interestingly, mice lacking PLZF display homeotic limb defects and a more anterior pattern of expression of some Hoxd genes, suggesting that PLZF could be a global regulator of this class of Hox genes (Barna et al., 2000) . Whether PLZF À/À embryos display abnormalities in Hoxb2 expression in the developing CNS remains to be examined. However, the lack of obvious segmental defects in the CNS of PLZF null embryos is not surprising as Hoxb2 and Hoxa2 mutants themselves do not show r3/r5 defects (Gendron-Maguire et al., 1993; Rijli et al., 1993; Barrow and Capecchi, 1996; Davenne et al., 1999) . It is likely that multiple factors regulate either different or overlapping programmes in the developing hindbrain. Although PLZF may not be able to compensate for the loss of some factors, such as Krox20 for example (Schneider-Maunoury et al., 1993; Swiatek and Gridley, 1993) , other factors like Krox20 may compensate for the loss of PLZF. Taken together our study indicates that HOX genes may be the major direct targets of PLZF and its leukaemia-associated fusion protein RARa-PLZF, in accord with many other leukaemia-associated proteins (Look, 1997) , such as MLL (Yu et al., 1995) .
Materials and methods

Plasmid construction
Construction of the PLZF, PLZFDPOZ and RARa1-PLZF expression vectors containing an N-terminal FLAG epitope tag ( FLAG PLZF) expression vectors has been previously described (Chen et al., 1994; Dong et al., 1996; Licht et al., 1996) . To construct r3/r5-TKluc, a 693 bp BamHI/BglII fragment containing the Hoxb2 r3 and r5 (r3/r5) enhancer region of the murine Hoxb2 locus (Sham et al., 1993) was subcloned into the BamHI site of pT109luc (Nordeen, 1988) upstream of the minimal HSV thymidine kinase (TK) promoter and luciferase (luc) gene. The PLZF binding site within the r3/r5 enhancer was mutated by PCR (from TACTGTAC to TACgGTAa) to generate the mutant reporter r3/r5mut-TKluc. For r3/r5-Kroxmut-Tkluc, a BamHI/BglII fragment consisting of the r3/r5 enhancer containing point mutations in all three Krox20 sites (Sham et al., 1993) was subcloned into pT109luc as above. Mutation of Box1 (AAAGTTTC to GGATCCGA) to generate the Box1 mutant reporter r3/r5-Boxmut-TKluc was carried out by PCR.
Transient transfections and reporter assays
Transient transfections using SuperFect reagent (Qiagen, San Clarite, CA, USA), luciferase assays and b-galactosidase assays were carried out as described previously . Cells were harvested for luciferase and b-galactosidase assays 24 h after transfection. Luciferase assays were normalized for b-galactosidase activity. In all cotransfection experiments, the total amount of transfected mammalian expression vector was kept constant. All transfections were performed at least three times in duplicate.
Protein expression and EMSAs
Nuclear extracts were prepared from 293T cells transiently transfected using the calcium phosphate precipitation method (Promega) or from KG1 cells. The 293T cells were transfected with a total of 6 mg DNA in 60 mm plates and harvested 40 h later; KG1 cells were harvested at log phase. Nuclear extracts were prepared according to previously described methods (Schreiber et al., 1989) . Protein expression was analysed by SDS-PAGE and visualized by Western blotting. For the EMSAs, double-stranded oligonucleotide probes (250 fmol) were end-labelled with (g 32 )ATP using T4 polynucleotide kinase. Nuclear extract (1-3 mg) was incubated with probe (approximately 5 fmol) for 40 min on ice in binding buffer (50 mm KCl, 2 mm DTT, 10 mm HEPES pH 7.9, 10% glycerol, 1 mg Poly(dI : dC), 2 mm MgCl 2 and 0.2% NP40). Protein/ DNA complexes were electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography. For competition assays, unlabelled oligonucleotides were included in the binding reaction. For antibody supershift assays, 1 mg antibody was incubated with nuclear extract for 45 min prior to addition of the probe.
Sequences of oligonucleotides used for cooperative binding studies (sense strands) were as follows: PLZF-RE(3), 5 0 -ggcTACTGTACggcacgttgaTACTGTAC-ggcacgttgaTACTG-TAC-3 0 (PLZF binding sites in uppercase letters); PLZF+Box1, 5 0 -gatcccgttgaTACTGTACggcagAAAGTTTCg-3 0 (PLZF binding site in uppercase letters, Box1 in bold uppercase letters); PLZF+mut-Box1, 5 0 -gatcccgttgaTACTGTACggcagggatccgag-3 0 (Box1 mutated, lowercase, bold); mutPLZF+Box1, 5 0 -gatcccgttgaTACgcTACggcagAAAGTTTCg (PLZF site mutated, mutations in lowercase letters).
Chromatin immunoprecipitation (CHIP) assay
The 293T cells in 10 cm plates were transfected with 5 mg reporter plasmid plus 10 mg expression vector using calcium phosphate. Immunoprecipitation of plasmid DNA plus associated histones was carried out approximately 40 h after transfection according to a previously published protocol (Braunstein et al., 1993) with the following modifications. Histone/DNA complexes were crosslinked by the addition of 1% formaldehyde to the medium and incubation at 371C for 10 min. After lysis, the chromatin was sonicated to 0.2-1.0 kb and diluted 10-fold in IP buffer (0.01% SDS, 1% Triton X-100, 2 mm EDTA, 20 mm Tris-HCl pH 8.0, 150 mm NaCl, plus protease inhibitors). Protein samples for Western blotting were taken prior to dilution; control samples for assaying input DNA were taken after dilution and de-crosslinked. Antiacetylated histone H4 polyclonal (Upstate Biotechnology) and monoclonal M2 anti-Flag (Sigma) antibodies were used for the immunoprecipitation, and the DNA/histone and DNA/ PLZF complexes were collected overnight with protein A/G sepharose beads (Santa-Cruz). Sequences spanning the PLZF binding site in the Hoxb2 r3/r5 enhancer were detected by semiquantitative PCR using primers 5 0 -GGATCCCCACT-TAACACCCAA-3 0 (forward) and 5 0 -CTTGGGAAACTG-CTCTTAACTAG-3 0 (reverse). The number of cycles was determined empirically to give results that fall within the linear range of this particular PCR assay.
LacZ expression analysis in chick embryos
Chick embryo electroporation was performed essentially as described (Itasaki et al., 1999) . At stage HH9 (8-10 somite) of development, a window was cut in the eggshell and the DNA vectors were injected into the neural tube of the embryos. Two electrodes (separation 4 mm) were placed in parallel along the anteroposterior axis of the embryo. The DNA was transferred unilaterally to the side of the positive pole (left-hand side of the embryos) by application of a series of electrical pulses. The right side of the neural tube constitutes an untransfected control. Embryos were cultured in ovo for 18 h and assayed for gene expression by staining for the reporter gene lacZ as previously described (Whiting et al., 1991) . In these experiments, a BTX T820 Electroporator with Enhancer 400 (Genetronics BTX, San Diego) was used to deliver electrical pulses; DNA concentrations were 0.1-1.0 mg/ml in H 2 O. The double-stranded oligonucleotides used to create the synthetic enhancers were: WT (PLZF-Box1) 5 0 -ttgaTACTGTACggcagAAAGTTTCgcg-3 0 ; mut-PLZF 5 0 -ttgaTcCgGcACggcagAAAGTTTCGcg-3 0 ; mut-Box1 5 0 -ttgaTACTGTACggcagggatccgagcg-3 0 ; PLZF/BOX1/Krox20 5 0 -cgttgaTACTGTACctagcctggAAAGTTTCtcacttcaagcatcc-GCGTGGGTGgggag-3 0 (Box1 sequence shown in bold, Krox20 site in italics, and PLZF site in plain script; all sites in uppercase except for mutations that are shown in lowercase letters). Multimers (three head-to-tail copies) were inserted into the pBGZ40 reporter vector, which contains a basal human b-globin promoter linked to the b-galactosidase gene and an SV40 polyadenylation signal (Yee and Rigby, 1993) .
